PAVmed Inc. (PAVM)

[MaineMan5]

This company could have a tremendous 2019 with everything they have going on with CarpX and EsoCheck, not to mention their other more minor devices. At a SP just over $1 with a $28M MC (plus 17M warrants at $1.60), this company is addressing potential markets of about $3B for their 2 main products. Even getting a small percentage of those markets could propel SP much much higher. Plus both appear to be be definite improvements on existing care.

Yes, consensus could not be reached by the consulting branch in August for CarpX (lead branch wanted approval) but it sounds like the company is doing everything right for their Jan 7 pre-submission meeting with FDA - pulling together significant data, bringing in outside expertise, requesting senior FDA decision makers attend, etc. so hopefully they will push it over the goal line this time. If they get their two products approved and in the market, I see a multi-bagger by this time next year. Of course there could be unforeseen issues, but having gone through this process once, I think they are dotting every "i" and crossing every "t" to get this approved. And I think they will be successful in both cases. GLTA.